#BeiGene presented its upcoming milestones for their #pipeline today at #JPM20, including projected approvals and submissions for #tislelizumab, #zanubrutinib, and #pamiparib. Why wait until the conference […]

#Roche presented its late stage pipeline today at #JPM20, with #tecentriq heading up #oncology with six anticipated indications, including expansions in #HCC, #TNBC, #bladdercancer, #melanoma, #ovariancancer, […]

A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developing the drug under the code […]

#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote […]

American Cancer Society Releases Facts & Figures for 2019 The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million […]

Kognitic is excited to be heading to #JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website to see how […]

Thank you Healthcare Tech Outlook for featuring Kognitic in the Top Ten Oncology Companies of 2019. We are thrilled to be listed alongside other innovative companies […]

A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been […]

We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitable access to clinical trials for all […]